Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder
Launched by VIVANTES NETZWERK FÜR GESUNDHEIT GMBH · Oct 12, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment called Group Acceptance and Commitment Therapy (ACT) for patients with psychotic disorders, such as schizophrenia or delusional disorder. The goal is to see if this group therapy can help patients better manage their symptoms, feel more satisfied with their treatment, and reduce the chances of needing to return to the hospital. The trial is currently recruiting participants aged 18 and older who have been diagnosed with one of the specific psychotic disorders.
If you or someone you know is considering joining, participants will take part in group therapy sessions designed to help them accept their experiences and develop a positive approach to their treatment. To be eligible, participants must have a diagnosis from a list that includes various types of psychotic disorders and should be able to understand and communicate during the sessions. It’s important to note that those who do not wish to participate or have difficulties with language or understanding may not be eligible. Overall, this trial could provide valuable insights into how group therapy can support individuals facing these challenging conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5 ("Schizophrenia Spectrum and Other Psychotic Disorders"):
- • Schizophrenia
- • Schizophreniform disorder
- • Schizoaffective disorder
- • Delusional disorder
- • Brief psychotic disorder
- • Psychotic disorder due to another disorder
- • Substance-induced/medication-induced psychotic disorder
- • Depressive episode with psychotic symptoms
- • Manic or bipolar episode with psychotic symptoms
- Exclusion Criteria:
- • Patients decline to participate in the treatment program
- • Language or intellectual abilities insufficient for study participation
About Vivantes Netzwerk Für Gesundheit Gmbh
Vivantes Netzwerk für Gesundheit GmbH is a leading healthcare provider based in Berlin, Germany, dedicated to delivering high-quality medical services and advancing clinical research. With a network of multiple hospitals and specialized facilities, Vivantes focuses on patient-centered care while fostering innovation in medical treatments and therapies. The organization is committed to conducting rigorous clinical trials that contribute to the advancement of medical knowledge and improve health outcomes, collaborating with various stakeholders to ensure the highest standards of research integrity and ethical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin Kreuzberg, Berlin, Germany
Patients applied
Trial Officials
Andreas Bechdolf, Prof. Dr.
Study Director
Senior consultant department of psychiatry Vivantes Klinikum Am Urban and Klinikum im Friedrichshain
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported